VC005 Tablets Placebo

DRUG6 trials

Sponsors

Jiangsu vcare pharmaceutical technology co., LTD

Conditions

Active Ankylosing SpondylitisInflammatory Bowel DiseasesModerate to Severe Atopic DermatitisNon-segmental VitiligoRheumatoid Arthritis

Phase 1

Pharmacokinetics and Pharmacodynamics Clinical Study of VC005 Tablets in Healthy Subjects

CompletedNCT05138770

Jiangsu vcare pharmaceutical technology co., LTDInflammatory Bowel Diseases

Start: 2021-11-18End: 2022-08-30Updated: 2022-09-02

A Phase I Clinical Study of VC005 Tablets in Subjects With Rheumatoid Arthritis.

CompletedNCT05874622

Jiangsu vcare pharmaceutical technology co., LTDRheumatoid Arthritis

Start: 2023-06-12End: 2023-10-25Updated: 2023-11-03

Phase 2

Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.

CompletedNCT05814939

Jiangsu vcare pharmaceutical technology co., LTDActive Ankylosing Spondylitis

Start: 2023-04-26End: 2024-05-11Updated: 2024-07-29

Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

CompletedNCT05997927

Jiangsu vcare pharmaceutical technology co., LTDModerate to Severe Atopic Dermatitis

Start: 2023-07-20End: 2024-07-09Updated: 2024-07-29

Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo

RecruitingNCT07172347

Jiangsu vcare pharmaceutical technology co., LTDNon-segmental Vitiligo

Start: 2025-10-31End: 2027-08-30Target: 120Updated: 2026-01-02

Phase 3

Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.

RecruitingNCT07172360

Jiangsu vcare pharmaceutical technology co., LTDActive Ankylosing Spondylitis

Start: 2025-12-26End: 2027-08-30Target: 420Updated: 2026-01-02